



# Comparison of miRNA Profiles of Primary Tumors and Metastatic Tumors of Salivary Gland Tumors and Their Role in Prognosis: A Systematic Review

Nooshin Mohtasham<sup>1,2</sup>, Mahtab Tarrah<sup>1</sup>, Fatemeh Arab<sup>3</sup>, Masoumeh Sadeghi<sup>4</sup>,  
\*Farnaz Mohajertehran<sup>5</sup>

1. Oral and Maxillofacial Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
2. Department of Oral and Maxillofacial Pathology, School of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran
3. Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
4. Department of Epidemiology, Faculty of Health, Mashhad University of Medical Sciences, Mashhad, Iran
5. Dental Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

\*Corresponding Author: Email: mohajertf@mums.ac.ir

(Received 18 Oct 2023; accepted 14 Jan 2024)

## Abstract

**Background:** MicroRNAs (miRNAs) are implicated in several biological processes, such as control of tissue homeostasis, cell signaling, differentiation, proliferation, neoplastic transformation, and activation/inhibition of apoptotic mechanisms. In this systematic review, we evaluated the changes in the expression pattern of miRNAs in salivary gland tumors (SGTs).

**Methods:** A comprehensive search was conducted in PubMed, and Scopus with no language and date restrictions in Feb 2023. All the studies on SGTs that evaluated miRNA profiling were included. Relevant data regarding the overexpression and down-regulation of the miRNAs were extracted. The quality of the included studies was evaluated with Newcastle–Ottawa checklist. The altered expression of miRNAs was evaluated between SGTs and normal cases, benign and malignant tumors, and primary and high-grade tumors.

**Results:** Thirteen studies were included in this systematic review. There were considerable differences between malignant and benign tumors regarding the miRNAs expression level. In the five studies, the miRNA profile of the primary tumors was compared with metastatic tumors to reveal the involvement of the miRNA in the prognosis of the salivary tumors. The miRNAs expression changes were correlated with tumor size, stage, recurrence, and occurrence of solid components. Perineural invasion and lymph node metastasis were also reported in ACC-LM cell line and recurrence of adenoid cystic carcinoma (ACC) tissues.

**Conclusion:** The miRNA profiling confirms their prognostic value in salivary gland tumors. Significant alternations of the miRNAs expression are useful for distinguishing different types of salivary tumors and malignant tumors from benign types. The miRNA expression changes also affect the prognosis of salivary tumors.

**Keywords:** Salivary gland neoplasms; MicroRNAs; Neoplasm metastasis; Biomarkers; Systematic review



## Introduction

Salivary gland tumors (SGTs) are large and diverse groups of benign and malignant neoplasms. The incidence of salivary gland tumors is approximately 3%-6% of all head and neck tumors, and they are a relatively uncommon heterogeneous group of neoplasms (1). There are significant clinical, morphological, and histological differences among SGTs that can lead to differential diagnosis and misleading information. The rarity of salivary tumors, diverse tumor subtypes, and the overlapping clinicopathological characteristics of the tumor subtypes lead to diagnostic challenges for the pathologist. There are almost 24 different subtypes of SGTs; pleomorphic adenoma (PA) is the most common benign salivary tumor whereas, mucoepidermoid carcinoma (MEC) and adenoid cystic carcinoma (ACC) are classified as malignant salivary gland tumors (2). MEC is mainly observed in pediatric patients, and ACC is associated with poor prognosis, perineural invasion, and distant metastasis of the lung, liver, or other organs. Surgical resection is the routine management of salivary tumors, and there are several preoperative diagnostic approaches including clinical examinations and imaging tools with or without fine needle aspiration cytology (FNAC) (3). The importance of salivary biomarkers as novel non-invasive tools for diagnosing cancer and systemic disease has been noticed recently in conditions ranging from oral diseases to systemic diseases (4-6).

MiRNAs are a class of small, non-coding RNAs (17-25 nucleotides) that bind to the 3'UTR of target mRNA to regulate mRNA and adjust the protein level (7, 8). The miRNAs are implicated in several biological processes, such as control of tissue homeostasis, cell signaling, differentiation, proliferation, neoplastic transformation, and activation/inhibition of apoptotic mechanisms. Changes in the expression pattern of miRNAs can affect the tissue environment, tumoral cell progression and vascularization. Therefore, miRNAs

might function as either oncogene or tumor suppressor under certain circumstances, and altered expression of miRNAs is involved in physiological and pathological conditions such as infectious diseases and cancer development (9-11). MiRNAs have been used as tissue-based prognostic markers and for the classification of malignancies, including breast, prostate, colon, pancreas, and thyroid cancers (12-16). Positive association has been previously observed between miRNA overexpression with the presence of lymph node metastasis, tumor size, and lung metastasis in SGTs. Lymph node metastasis and clinical prognosis affect the survival of patient (17).

Therefore, we aimed to systematically review the studies on miRNAs profiling of different types of SGTs to consider altered expression (up-regulation and down-regulation) of miRNAs and their prognostic effect in malignant tumors compared with benign types.

## Materials and Methods

The Preferred Reporting Item for Systematic Reviews and Meta-analysis (PRISMA) statement was used to guide the present work (18).

### *Search strategy*

A comprehensive search was performed through two databases of PubMed and Scopus. The following search strategy was used in each database: RNA AND (salivary gland tumor OR salivary gland carcinoma OR salivary adenocarcinoma). Screening of the databases was done in Feb 2023. A comprehensive search was performed by two authors, and for those articles on which the authors disagreed, the opinion of another author was sought. If the disagreements could not be resolved, the consensus of all three authors was used.

We did not have any language or publication date restriction in our search strategy. The title and abstract of initial search results were screened by two

independent investigators using End-Note, for all relevant studies published. Duplicate articles were omitted. The full texts of the remaining articles were evaluated to exclude the irrelevant articles. The reference lists of identified studies were reviewed for relevant articles not picked up from the search strategy.

#### *Inclusion and exclusion criteria*

Inclusion criteria were all the studies specifically reporting on miRNA profiling and expression level of different miRNAs of malignant and benign salivary gland tumors. Case reports, conference proceedings, personal communications, letters to editor, experimental articles, reviews, and articles not reporting the miRNA profile of the SGTs were all excluded.


#### *Data Extraction and Quality Assessment*

Data were extracted independently by two authors. Information extracted from each study were summarized into an Excel table (Office Suite, Microsoft Corp.), which considered: The details of

the study (title, authors, publication year, and country), case, control, miRNA profiling method, type of salivary gland tumor examined, up-regulated and down-regulated miRNAs. Two reviewers independently assessed the quality with Newcastle–Ottawa and extracted data in the Pre-defined checklist. Quality of our selected articles was evaluated with eight-item Newcastle–Ottawa (NOS) checklist for case–control studies. This instrument has three domains: 1) selection of participants, 2) comparability, and 3) outcome ascertainment.

## Results

The process of searching and selecting relevant studies has been described in Fig. 1. In total, 19 studies were included in this systematic review as the most relevant articles. In 13 studies, miRNA profile of the benign and malignant salivary tumors was compared with the normal tissue sample (19-28).



**Fig. 1:** Flowchart for the search strategy and selection process

The miRNA profile of the PA tissue samples was compared with normal tissue in 3 of the studies (25, 29). MiRNA profile of the MEC tissue was compared with the normal tissue in three of the studies (20, 25, 28). The majority of the studies (6/10) evaluated miRNA profile of the ACC tissue samples with the normal tissue (19, 21, 23-25, 27). Only one study evaluated the miRNA profile of the warthin tumor in comparison with normal salivary tissue (22). Ten studies used tissue samples, two studies examined cell lines, and one study used plasma sample for comparing the miRNA

profile of the benign and malignant salivary tumor with normal cases. The study of Cinpolat et al. evaluated the miRNA expression profile on serum, saliva, and tissue samples of the patients (22). Summarized characteristics of the studies evaluated miRNA profile of malignant or benign samples in comparison with normal samples are presented in Table 1. The miRNA profiling was performed by miRNA microarray followed by RT-PCR for validating the results in most of the studies.

**Table 1:** Characteristics of the articles compare miRNA profile in salivary gland tumors compared with normal cases

Author/ year	Number Case/Control	Sample	Method	MiRNA profile change	Most highly changed	
					Up regulated miRNA	Down regulated miRNA
Zhang/ 2009 Australia (29)	PA :17 Normal:17	Tissue	Microarray data analysis and qRT-PCR	Up-regulated: 17 Down-regulated: 5	miR-140, miR-229-3p, miR-29c miR-302c, miR-376a	let-7a, miR-375
Cinpolat/2017 Turkey (22)	Warthin tumor: 9 PA: 7 Normal: 17	Plasma	qRT-PCR	Up-regulated: 0 Down-regulated: 8	No	miR-21, miR-23a, miR-27a miR-223, miR-125b, miR-126, miR-146a, miR-30e
Binmadi/2018 USA (20)	MEC:6 Normal:3	Tissue	The TaqMan Human miRNA Cards Array and qRT-PCR	Upregulated: 63 Downregulated:5	miR-302a, miR-490 miR-21 miR-22 miR-205	miR885-5p, miR-375 miR-19a, miR-363-3p miR-192
Naakka/2022 Brazil (28)	MEC: 25 Normal: 6	Tissue	MiRNA expression analysis and qRT-PCR	Upregulated: 18 Downregulated:28	miR-21-5p, miR-22-3p, miR-181a-5p miR-205-3p miR-224-3p	miR-363-3p, miR-625-5p miR-885-5p miR-892b miR-1288-3p
Mitani/ 2013 USA (24)	ACC:13 Normal:4	Tissue	Microarray and qRT-PCR	Upregulated: 19 Downregulated:36	miR17-92 cluster miR-455-3p, -455-5p, miR-181 miR-183 miR106 b-25 miR106a-363 miR-1271-5p	miR-375, miR-142-3p miR-142-5p, miR-148, miR-155, miR-33b miR-29c, miR-14 miR-205
Andreasen/2018 Denmark (19)	primary ACC:11 Normal: 11	Tissue	MicroRNA array	Upregulated: 1 Downregulated:7		miR-1199-3p, mir-4717-5p miR-610, miR-68785p miT-519, miR-5572

Table 1: Continued....

Andreasen/2018 Denmark (19)	Metastatic ACC:11 Normal:11	Tissue	MicroRNA array	Upregulated: 4 Downregulated:7	miR-922, miR-1271-3p miR6790, miR-6894	miR-6865, miR-1199-3p miR4717-5p, miR499a miR-4790, miR3936 miR-127
Andreasen/2018 Denmark (30)	Primary and metastatic ACC:64 Normal:10	Tissue	The Affymetrix miRNA 4.1 array platform	Upregulated:22 Downregulated:25	MiR-181d-5p MiR-455-5p	miR-148a-5p miR-885 miR-29c-3p miR-139
Han/2018 China (23)	ACC: 6 Normal:6	Tissue	HT-NGS technology, qRT-PCR	Upregulated:15 Downregulated:25	miR-520a-5p, miR-445-5p miR-181b	miR-885-5p, miR-375 miR-20b-5p
Kiss/2015 Hungary (27)	ACC:2 Normal:1	Tissue	Affymetrix miRNA Array	Upregulated:7 Downregulated:9	miR-17 miR-20a	Let-7b miR-193b
Matse /2015 China (31)	SGTs: 12 Contralateral Normal tissue:12	Parotid Saliva	RT-qPCR	Upregulated:1 Downregulated:6	Has-miR103a-3p	Has-miR-211 Has-miR-296-5p Has-miR-425-5p Has-miR-1233 Has-miR1267 Has-miR1825 miR-140
Boštjančič/2017 Slovenia (17)	SGTs:70 Normal:11	Tissue	Rt-qPCR	Upregulated:2 Downregulated:1	MiR-133b miR- 99b	miR-140
Gao/2014 USA (32)	ACC:12 Normal:12	Tissue	Microarray assay qRT-PCR	Upregulated:11 Downregulated: 11	miR-455-3p miR-181b/a miR-146a miR-106b	miR-375 miR-31 miR-150 miR-152
Santos/2017 Brazil (25)	ACC: 2 Normal: 11	Tissue	TaqMan MicroRNA RT Reverse Transcription Kit and qRT-PCR	Upregulated:1 Downregulated: 5	miR-9	miR-16 miR-221 miR-122 miR-195
Santos/2017 Brazil (25)	PA: 2 Normal: 11	Tissue	TaqMan MicroRNA RT Reverse Transcription Kit and qRT-PCR	Upregulated:1 Downregulated: 4	miR-9	miR-221 miR16 miR132 miR-17
Santos/2017 Brazil (25)	MEC: 2 Normal:9	Tissue	TaqMan MicroRNA RT Reverse Transcription Kit and qRT-PCR	Upregulated:0 Downregulated: 3	NO	miR-9 miR-16 miR-221

Adenoid cystic carcinomas (ACC), mucoepidermoid carcinomas (MEC) and pleomorphic adenomas (PA), SAM: Significant analysis of microarray, ACC-M: a highly metastatic SACC cell line

In four studies, miRNA profile of the malignant salivary gland tumors was compared with benign salivary tumors using tissue, plasma, and saliva. Santos et al. obtained no significant difference between malignant and benign tumors regarding the overexpression of the miRNAs (25). Cinpolat et

al. showed no significant difference between malignant and benign tumors regarding down-regulation of the miRNAs (22). Characteristics of the studies on malignant versus benign salivary tumor miRNA profile differences are summarized in Table 2.

**Table 2:** Characteristics of the articles evaluated the miRNAs profile of the malignant salivary tumor compared with benign salivary tumors

Author	Comparison		Method	Malignant vs. benign	
	Malignant	Benign		Up-regulated	Down-regulated
De-naro/2019 Italy (33)	MEC:6 ACC:4 ACC*:1 SDC:1 cystadenocarcinoma:1 adenocarcinoma:1	PA: 8	nCounter human miRNA expression assay	N: 32 miR-17-92 cluster (miR-93, miR-106a, miR106-b, miR-20a) miR-21-5p, miR-181a-5p miR-199a-5p, miR-4286 let-7g-5p, miR-17-5p, miR-199a(b)-3p, miR-15b-5p miR-126-3p, miR-126-3p miR-320e, miR-19b-3p miR-200b-3p, miR-222-3p miR-146a-5p, miR-374a-5p miR-1246, miR-150-5p	N:29 miR-376c-3p, miR-125b-5p miR-376a-3p, miR-127-3p miR-136-5p, miR-495-3p let-7e-5p, miR-377-3p miR-99b-5p, miR-100-5p miR-382-5, miR-195-5p miR-582-5p, miR-411-5p miR-379-5p, miR-154-5p miR-543, miR-135a-5p miR-27b-3p, miR-9-5p, miR-140-5p
Cinpolat/2017 Turkey (22)	Primary SCC:2 High grade MEC:1 ACC:1	Warthin tumors: 9 PA:7	Tissue MicroRNA isolation qRT-PCR	N:5 miR-21, MiR-146b MiR-31, MiR-345 MiR-199a,	-
Cinpolat/2017 Turkey (22)	N:4 SCC:2 MEC:1 ACC:1	N:14 Warthin tumors: 9 PA:7	Plasma MicroRNA isolation qRT-PCR	miR-199a miR-30e	-
Matse /2013 USA (34)	SCC:9 Adenocarcinoma NOS:2 ACC*:3 MEC:3 SDC:3 Undifferentiated carcinoma:1 Carcinoma ex-pleomorphic adenoma:1 ACC:2 Myoepithelial carcinoma:1 BCC:1	PA:13 Warthin tumor:5 Basal cell adenoma:1	Saliva TaqMan microRNA assays qRT-PCR	mmu-miR-140-5p, miR-374, miR-222, miR-15b, let-7g, miR-132, miR-140-5p hsa-let-7g, miR-132, miR-519b-3p, miR-223, -miR-30a-3p	hsa-miR-519b-3p hsa-miR-520C-3p hsa-miR-520D-3p
Kim/2022/ Korea (35)	CXPA CA portion (13) four SDC: 4, epithelial-myoepithelial carcinoma: 2 MEC: 2 Adenocarcinoma NOS: 3 Clear cell carcinoma: 1 Oncocytic carcinoma: 1 CXPA (13)	CXPA PA portion (13)      Benign PA (16)	miRNA sequencing	miR-21-3p, miR-183-5p miR-182-5p, miR-425-5p miR-96-5p, miR-200a-3p miR-181a-3p, miR-505-3p	miR-455-3p, miR-140-5p miR-483-5p, miR-125b-5p miR-125a-5p
Kim/2022/ Korea (35)			miRNA sequencing	miR-196a-5p, miR193a-3p miR193b-3p, miR-29c-3p miR-331-3p, miE361-3p	Let-7a-3p, miR-27a-3p miR-9-5p, miR-135a-5p miR-455-5p, miR218-5p miR181d-5p, miR369-3p miR132-5p

ACC\*: Acinic cell carcinoma, SDC: Salivary duct carcinoma, SCC: Squamous cell carcinoma, BCC: Basal cell carcinoma, CXPA: Carcinoma ex pleomorphic adenoma, CA: carcinomatous portion, PA: pleomorphic adenoma.



To reveal the involvement of the miRNA in the prognosis of the salivary tumor, miRNA profile of the primary or benign salivary gland tumor was compared with miRNA profile of the metastatic and high-grade tumor, in five of the studies (19, 24, 28, 36). According to these studies, altered expression of the miRNAs is correlated with tumor size, stage, recurrence, and occurrence of solid components. Perineural invasion and lymph node metastasis were also reported in ACC-LM cell and recurrence ACC tissues by two authors (24, 36).

Andreasen et al reported no correlation between miRNA expression and stage of the ACC (19). In Table 3, data of the studies on miRNA profiling of the metastatic salivary gland tumor with poor survival compared with primary tumor are summarized.

Data regarding the quality assessment of the included studies based on the Newcastle Ottawa scale are presented in Table 4.

**Table 3:** Studies evaluated altered miRNA expression changes of the salivary gland tumor with worse survival

Author	Samples	Up-regulated	Down-regulated	Clinicopathologic changes
Naakka/2022 Brazil (28)	High grad MEC (N:9) vs. low (N:20) or intermediate (N:7) grade MEC	miR-205-5p miR-224-5p	miR-582-5p miR-3125 miR-4324 miR-139-3p miR-145-3p miR-148a-3p miR-186-5p miR-338-3p miR-363-3p	Invasion and migration
Feng/2017 USA (36)	SACCLM vs. SACC83	miR-99a-5p miR-155-5p	miR-130a-3p miR-342-3p miR-205-5p miR-205-5p	Perineural invasion
Feng/2017 USA (36)	Recurrent ACC (6) vs. primary ACC (6)	miR-155-5p miR-342-3p	miR-205-5p	Perineural invasion
Andreasen/2018 Denmark Genetic (30)	Metastatic ACC (22) vs. primary ACC (25)	No difference	No difference	Not reported
Chen/ 2014 China (21)	ACC-2 vs. ACC-M	N: 20 miR-4487 miR-4430 miR-5096 miR-1285-3p	N: 18 miR-5191 miR-3131 miR-4278 miR-4498	Not reported
Wang/2018 China (37)	ACC-M vs. ACC-2 Tissue	miR-146a-5p/3p	miR-361-5p/3p miR-338-5p/3p miR-374c miR-1180	-
Andreasen/2018 Micro Denmark (19)	ACC Validation group:120	hsa-mir-21, hsa-mir-181a-2 hsa-mir-152 mir-4676 has-mir-6835-3p		
Mitani/2013 USA (24)	ACC tissue Patients died:8 vs. Alive patients:22	miR-17-92 cluster (miR-17, and - 20a) let-7a miR-150 miR-9	-	Tumor size (108 miRNA) Tumor stage(18 miRNAs) Tumor recurrence (39 miRNAs) Lymph node metastasis (13 miRNAs) Solid component

SACC-83: adenoid cystic carcinoma cell lines with low lung metastasis rate. SACC-LM daughter cell line of SACC-83 with high lung metastasis.

**Table 4:** Quality control of the included studies.

<i>Author/ year</i>	<i>Adequate definition of case</i>	<i>Representative of cases</i>	<i>Selection of control</i>	<i>Definition of control</i>	<i>Comparability of cases and controls on the basis of the design or analysis</i>	<i>Same method of ascertainment for cases and controls</i>
Zhang/ 2009(29)	*	*	*	*	*	*
Cinpolat/2017(22)	*	*	*	*	*	*
Binmadi/2018(20)	*	*	*	*	*	*
Naaakka/2022(28)	*	*	*	*	*	*
Chen/2014(21)	*	*	*	*	*	*
Mitani/2013(24)	*	*	*	*	*	*
Andreasen/2018(30)	*	*	*	*	*	*
Andreasen/2018(19)	*	*	*	*	*	*
Matse/2015 (31)	*	*	*	*	*	*
Matse/2013 (34)	*	*	*	*	*	*
Boštjančič /2017 (17)	*	*	*	*	*	*
Han/2018(23)	*	*	*	*	*	*
Kiss/2015(27)	*	*	*	*	*	*
Denaro/2019(33)	*	*	*	*	*	*
GAO/2014(32)	*	*	*	*	*	*
Kim/2022(35)	*	*	*	*	*	*
Wang/2018 (37)	*	*	*	*	*	*
Feng/2017(36)	*	*	*	*	*	*
Santos/2017(25)	*	*	*	*	*	*

## Discussion

The current study showed that miRNA expression patterns have a role in the tumorigenesis of benign and malignant salivary gland tumors.

### *Up-regulated miRNAs*

The up-regulation of the miR-376a, miR-301, and miR-21 have been reported in cervical and pancreatic cancers; similar increased expression was detected in benign salivary tumors of PA compared with healthy tissue (26, 38, 39). The miR-21 is one of the most prominent miRNAs that is up-regulated during cancer progression and is associated with poor prognosis. The over-expression of the miR-21 has been mentioned in six of the studies

that evaluated PA, MEC, and ACC tissues miRNAs compared with normal salivary tissue (20, 22, 26, 28, 33, 40); whereas, in the study of Cinpolat et al, decreased expression of the miR-21 was observed in plasma sample of the PA cases compared with normal ones (22). Despite the decreased expression of the mir-21 in plasma samples of the PA than normal cases, significantly increased expression of the miR-21 was observed in malignant PA tissue samples compared with benign PA tissue samples. Aberrant expression of miR-21 has been reported in previous studies as a possible oncogene and a key determinant of malignant progression and metastases (41-43). MiR-21 has also been reported as a stable miRNA that is overexpressed in head and neck squamous cell carcinomas (SCCs) with the following characteristics of



anti-apoptotic effects, promoting cell invasion, proliferation, and metastases (44). Therefore, suppression of miR-21 may provide a potential approach for treating advanced salivary gland tumors. Similar expression of miR-30e to miR-21 might be due to their role in tumor development. MiR-30e is another biomarker that was over-expressed in plasma samples of malignant salivary tumors compared with benign tumors, and down-expressed in plasma samples of benign salivary tumors (PA) compared to controls (22).

MiR-302a, miR-544, miRNA-205, and miRNA-22 were the most overexpressed miRNAs in MEC salivary gland tumors evaluated in the included studies (20, 28). Based on the studies, overexpression of the miRNAs in MEC is involved in irregular gene expression and cell invasion during cancer tumorigenesis and progression. MECs have various clinicopathological behavior, so detecting the disease prognosis and decision for further treatment is challenging (45).

Although miR-205 was increased in MEC primary and metastatic tissues compared with normal control tissue (20, 28), studies on ACCs cell lines with lung metastasis and recurrent ACC tissue showed significant reduction in miR-205 expression compared with primary ACC and ACC cell line without metastasis (36).

In the study of Cinpolat et al., comparing tissue and plasma samples of malignant salivary tumors of ACC, MEC, and SCC with benign salivary tumors of warthin tumors and PA, showed increased expression of the miR-199a, miR-146b, and miR-31 (22). Their results were confirmed by the study of Denaro et al. on malignant tumors miRNA profiling (33). The prognostic value of these miRNAs has been shown in melanoma, prostate, thyroid, colon, hepatocellular, and gastric cancers. Based on these studies, increased expression of the miR-146b, 31, and 199a is associated with decreased survival rate, so confirm their prognostic value (13, 46-50).

The overexpression of miRNAs such as miR-455 in salivary gland tissues is proposed a complementary tool to diagnose challenging cases of ACC and MEC (24, 51). Further investigations are needed

to reveal the functional role of miR-455 in tumorigenesis and progression of the ACCs. Since there is a diagnostic challenge for ACCs, mir-455 is potentially involved in ACCs pathogenesis and have diagnostic potential.

Different expression of the miRNAs between malignant and benign tumors has been evaluated in four studies (22, 25, 33, 34). The expression of the miR-9 was examined in the study of Santos et al. who observed no significant difference of miR-9 expression between malignant ACC and MEC salivary tumors compared with PA. Similar expression levels of the miR-9 between malignant and benign tumors might be related to the controversial effect of miR-9 across tumor types (25). Increased expression of the miR-15b in malignant salivary tumors compared with benign types was also associated with tumorigenesis and poor prognosis reported by two groups. Overexpression of miR-15b could block the apoptosis pathway and reduce the expression of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) gene in colorectal and gastric cancers (33, 34).

#### *Down-regulated miRNAs*

We identified that significantly decreased expression of some miRNAs was related to high-grade salivary tumors and could be implicated in tumorigenesis and invasion of cancers. Zhang et al. reported dramatically decreased expression of miR-144, miR-140, miR-375, and let-7 in benign salivary gland tumors of PA (29). Reduced expression of the mentioned miRNAs such as let-7 has been previously reported in lung cancer (52, 53). The miRNA-885-5p, miRNA-375, miR-363-3p, and miR-4324 were among the miRNAs that revealed significant down-expression in malignant salivary gland tumor of MEC and ACC when compared with the normal tissue (20, 23, 24). These miRNAs are putative prognostic biomarkers that are down regulated following tumor progression (20, 28). The decreased expression of the miR-375 has been confirmed in other cancerous tissues, such as gastric carcinoma, and renal and pancreatic cancers. Based on three of the included studies, down-regulation of miR-885-5p plays an important role in carcinogenesis of the salivary gland adenoid cystic

carcinoma (SACCs), and the SCUBE3 mRNA was reported as its primary target (20, 23, 28). Let-7a and b are a member of the miRNA family involved in both normal development and cancer progression and has oncogenic effect following their over-expression. However, loss of expression of let-7a is shown to be associated with the development and progression of the cancers (27, 29).

MiR-125b was also among the miRNAs that showed down-regulation not only in plasma samples of the PA cases compared with plasma of the normal cases (22), but also in tissue samples of malignant salivary gland tumors compared with benign types tissue samples (33). Normal expression of miR-125 has been reported as a tumor suppressor in hepatocellular, breast and gastric cancers; however, the dysregulation of the miR-125 has resulted in alternations in chromosome 11 that lead to salivary gland MEC, head and neck SCC, oral cancers, and metastasis in many tumors (54-56).

The study of Liang et al. on salivary ACC cell lines, showed that lower level of miR-125 is positively associated with metastatic phenotype (57). Down-regulation of some miRNAs was also observed in SACC tissues; however, the correlation between down-regulation of these miRNAs and aggressiveness of the tumor behavior is not apparent (24). Down-regulation of miR-148 in ACC compared to normal tissue reported by two of the studies was similar to its decreased expression in high-grade MEC versus normal or intermediate-grade and primary MEC compared to normal tissue, reported by Naakka et al. MiRNA-148 expression acts as a tumor suppressor by inhibiting cell proliferation, growth, migration, and invasion (28). However, down-regulation of the miRNA-148 increases the proliferation, invasion, and metastasis of tumor cells through different target genes (58). Several underlying mechanisms might be responsible for oncogenic effect of the down-regulation of miRNAs, including overexpression of the PLAG1, RAS oncogene, and HMGA2 (42, 59). Based on the studies on PA as the most frequent benign salivary gland tumor, evaluating the miRNA profile has diagnostic value with 100% accuracy for discriminating pleomorphic adenoma from the normal tissue (29). Recent studies have

documented the significant association between the miRNA gene's location to fragile sites, and genomic regions involved in cancers that can affect the proliferative signaling, cell death, activating invasion and metastasis (60, 61). Deregulation of the miRNA expression might be the consequence of various mechanisms, such as amplification or deletion of miRNA genes, abnormal transcriptional control of miRNA, deregulated epigenetic changes, chromosomal abnormalities, and defects in miRNA biogenesis machinery.

### *Prognostic value of miRNA*

Dysregulation of the miRNA expression has been observed in metastatic or high-grade salivary gland tumors which shows the involvement of the miRNA in progression of cancer and poor prognosis of the disease. The study of Chen et al confirmed the association between altered expression of miRNAs (upregulation of miR-4487, miR-4430, and miR-486-3p) and hematogenous spread of SACC to lungs using miRNA microarray and qPCR analysis, which might be helpful in providing a novel molecular therapeutic target for the treatment of SACC (21). MiR-17-92 cluster has shown an important role in progression of different tumor types. The miR-17-92 cluster (miR-17 and miR-20, miR-93, miR-106) overexpression revealed statistically significant association with aggressiveness of tumor behavior and poor survival of ACC, MEC, and SCC compared with benign salivary tumors (24, 33). Mitani et al obtained significant relation between upregulation of the miR-20a, -17, and -9 and occurrence of solid components in ACC tissues. They also reported positive association between overexpression of let-7a and miR-150 with size, stage, lymph node metastasis, and recurrence of the ACC (24). The overexpression of miR-133 has also shown positive relation with tumor size and poor prognosis in salivary tumors compared with healthy tissue (17).

MiR-155 was evaluated in three studies, and showed upregulation in salivary ACC with lung metastasis cell lines and tissue samples compared with primary ACC (36); however, in comparison with healthy controls, miR-155 expression was decreased in ACC tissue samples (24). The increased

expression of the miR-155 was associated with perineural invasion through increased expression of the UBA2 gene as a mediator of the SACC metastasis.

MiR-582-5p and -4323 were another miRNA that showed down regulation in high grade MEC compared with low grade MEC and were influential on invasion and migration of the tumor cells through the target genes of EZH2, PIK3CA, and PTEN. High-grade MEC showed decreased expression of miR-582-5p and miR-4324 compared with intermediate/low grade MEC associated with shorter overall survival and worse prognosis by overexpression of the EZH2 and PTEN target genes. The overexpression of EZH2 was previously reported in MEC, myoepithelial carcinoma of salivary glands, and ACC. In another study performed by Andreasen et al., miRNAs were differentially expressed between primary ACC and metastases as compared to normal salivary gland tissue. However, there was no difference between primary and metastatic lesions, and they reported no correlation between miRNA profile expression and tumor stage, and obtained no prognostic value for altered miRNAs expression (19). The inconsistent results showed that primary ACC have inherent metastatic capacity and are similar to their metastatic forms regarding the miRNA profile (30). The major limitation of the current study was small sample size of most of the studies and low number of studies with follow up duration to evaluate the miRNA profile in recurrence tumors and metastatic tissues. Larger cohorts with long term follow up are needed increase the accuracy of the results.

## Conclusion

miRNA profiling confirms their prognostic value in salivary gland tumors. Significant alternations of the miRNAs expression are useful for distinguishing different types of the salivary tumors and malignant tumors from benign types. MiRNA expression changes also affect the prognosis of the salivary tumors. However, further studies are needed

to obtain consistent results and reveal the specific diagnostic and prognostic values of miRNAs.

## Journalism Ethics considerations

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

## Acknowledgements

The Department of the Research Council of Mashhad University of Medical Sciences, Faculty of Dentistry, supported the project financially (Grant number: 4002234).

## Conflict of interest

The authors declare that there is no conflict of interests.

## References

1. de Oliveira FA, Duarte EC, Taveira CT, et al (2009). Salivary gland tumor: a review of 599 cases in a Brazilian population. *Head Neck Pathol*, 3 (4):271-5.
2. Mairembam P, Jay A, Beale T, et al (2016). Salivary gland FNA cytology: role as a triage tool and an approach to pitfalls in cytomorphology. *Cytopathology*, 27 (2):91-6.
3. Pusztaszeri MP, Faquin WC (2015). Update in salivary gland cytopathology: Recent molecular advances and diagnostic applications. *Semin Diagn Pathol*, 32 (4):264-74.
4. Xiao H, Wong DT (2011). Proteomics and its applications for biomarker discovery in human saliva. *Bioinformation*, 5 (7):294-6.
5. Zhang L, Farrell JJ, Zhou H, et al (2010). Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. *Gastroenterology*, 138 (3):949-57.e1-7.
6. Gonzalez-Begne M, Lu B, Han X, et al (2009). Proteomic analysis of human parotid gland exosomes by multidimensional protein

- identification technology (MudPIT). *J Proteome Res*, 8 (3):1304-14.
7. Condrat CE, Thompson DC, Barbu MG, et al (2020). miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis. *Cells*, 9 (2):276.
  8. Etheridge A, Lee I, Hood L, Galas D, Wang K (2011). Extracellular microRNA: a new source of biomarkers. *Mutat Res*, 717 (1-2):85-90.
  9. Jang JH, Lee TJ (2021). The role of microRNAs in cell death pathways. *Yeungnam Univ J Med*, 38 (2):107-117.
  10. Peng Y, Croce CM (2016). The role of MicroRNAs in human cancer. *Signal Transduct Target Ther*, 1:15004.
  11. Mirhashemi M, Ghazi N, Saghravani N, et al (2020). Evaluation of CD24 and CD44 as cancer stem cell markers in squamous cell carcinoma and epithelial dysplasia of the oral cavity by q-RT-PCR. *Dent Res J (Isfahan)*, 17 (3):208-212.
  12. Wang JY, Wang CL, Wang XM, et al (2017). Comprehensive analysis of microRNA/mRNA signature in colon adenocarcinoma. *Eur Rev Med Pharmacol Sci*, 21 (9):2114-2129.
  13. Wang SY, Shiboski S, Belair CD, et al (2014). miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance. *PLoS One*, 9 (6):e98597.
  14. Alemar B, Izetti P, Gregório C, et al (2016). miRNA-21 and miRNA-34a Are Potential Minimally Invasive Biomarkers for the Diagnosis of Pancreatic Ductal Adenocarcinoma. *Pancreas*, 45 (1):84-92.
  15. Baloch ZW, Asa SL, Barletta JA, et al (2022). Overview of the 2022 WHO Classification of Thyroid Neoplasms. *Endocr Pathol*, 33 (1):27-63.
  16. Jahanbin A, Hasanzadeh N, Abdolhoseinpour F, et al (2014). Analysis of MTHFR gene C. 677C> T and C. 1298A> C polymorphisms in Iranian patients with non-syndromic cleft lip and palate. *Iran J Public Health*, 43 (6):821-7.
  17. Boštjančič E, Hauptman N, Grošelj A, et al (2017). Expression, Mutation, and Amplification Status of EGFR and Its Correlation with Five miRNAs in Salivary Gland Tumours. *Biomed Res Int*, 2017:9150402.
  18. Shamseer L, Moher D, Clarke M, et al (2015). Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ*, 350:g7647.
  19. Andreassen S, Tan Q, Agander TK, et al (2018). MicroRNA dysregulation in adenoid cystic carcinoma of the salivary gland in relation to prognosis and gene fusion status: a cohort study. *Virchows Arch*, 473 (3):329-340.
  20. Binmadi NO, Basile JR, Perez P, et al (2018). miRNA expression profile of mucoepidermoid carcinoma. *Oral Dis*, 24 (4):537-543.
  21. Chen W, Zhao X, Dong Z, et al (2014). Identification of microRNA profiles in salivary adenoid cystic carcinoma cells during metastatic progression. *Oncol Lett*, 7 (6):2029-2034.
  22. Cinpolat O, Unal ZN, Ismi O, et al (2017). Comparison of microRNA profiles between benign and malignant salivary gland tumors in tissue, blood and saliva samples: a prospective, case-control study. *Braz J Otorhinolaryngol*, 83 (3):276-284.
  23. Han N, Lu H, Zhang Z, et al (2018). Comprehensive and in-depth analysis of microRNA and mRNA expression profile in salivary adenoid cystic carcinoma. *Gene*, 678:349-360.
  24. Mitani Y, Roberts DB, Fatani H, et al (2013). MicroRNA profiling of salivary adenoid cystic carcinoma: association of miR-17-92 upregulation with poor outcome. *PLoS One*, 8 (6):e66778.
  25. Santos PRB, Coutinho-Camillo CM, Soares FA, et al (2017). MicroRNAs expression pattern related to mast cell activation and angiogenesis in paraffin-embedded salivary gland tumors. *Pathol Res Pract*, 213 (12):1470-1476.
  26. Zhang X, Cairns M, Rose B, et al (2009). Alterations in miRNA processing and expression in pleomorphic adenomas of the salivary gland. *Int J Cancer*, 124 (12):2855-63.
  27. Kiss O, Tóké AM, Vranic S, et al (2015). Expression of miRNAs in adenoid cystic carcinomas of the breast and salivary glands. *Virchows Arch*, 467 (5):551-62.
  28. Naakka E, Barros-Filho MC, Adnan-Awad S, et al (2022). miR-22 and miR-205 drive tumor aggressiveness of mucoepidermoid



- carcinomas of salivary glands. *Front Oncol*, 11:786150.
29. Zhang X, Cairns M, Rose B, et al (2009). Alterations in miRNA processing and expression in pleomorphic adenomas of the salivary gland. *Int J Cancer*, 124 (12):2855-2863.
  30. Andreasen S, Agander TK, Bjørndal K, et al (2018). Genetic rearrangements, hotspot mutations, and microRNA expression in the progression of metastatic adenoid cystic carcinoma of the salivary gland. *Oncotarget*, 9 (28):19675-19687.
  31. Matse JH, Yoshizawa J, Wang X, et al (2015). Human Salivary Micro-RNA in Patients with Parotid Salivary Gland Neoplasms. *PLoS One*, 10 (11):e0142264.
  32. Gao R, Cao C, Zhang M, et al (2014). A unifying gene signature for adenoid cystic cancer identifies parallel MYB-dependent and MYB-independent therapeutic targets. *Oncotarget*, 5 (24):12528-42.
  33. Denaro M, Navari E, Ugolini C, et al (2019). A microRNA signature for the differential diagnosis of salivary gland tumors. *PLoS One*, 14 (1):e0210968.
  34. Matse JH, Yoshizawa J, Wang X, et al (2013). Discovery and prevalidation of salivary extracellular microRNA biomarkers panel for the noninvasive detection of benign and malignant parotid gland tumors. *Clin Cancer Res*, 19 (11):3032-8.
  35. Kim H, Eun S, Jeong WJ, et al (2022). Identification of differentially expressed microRNAs as potential biomarkers for carcinoma ex pleomorphic adenoma. *Sci Rep*, 12 (1):13383.
  36. Feng X, Matsuo K, Zhang T, et al (2017). MicroRNA Profiling and Target Genes Related to Metastasis of Salivary Adenoid Cystic Carcinoma. *Anticancer Res*, 37 (7):3473-3481.
  37. Wang S, Zhang L, Shi P, et al (2018). Genome-wide profiles of metastasis-associated mRNAs and microRNAs in salivary adenoid cystic carcinoma. *Biochem Biophys Res Commun*, 500 (3):632-638.
  38. Lui WO, Pourmand N, Patterson BK, et al (2007). Patterns of known and novel small RNAs in human cervical cancer. *Cancer Res*, 67 (13):6031-43.
  39. Lee EJ, Gusev Y, Jiang J, et al (2007). Expression profiling identifies microRNA signature in pancreatic cancer. *Int J Cancer*, 120 (5):1046-54.
  40. Andreasen S, Therkildsen MH, Grauslund M, et al (2015). Activation of the interleukin-6/Janus kinase/STAT3 pathway in pleomorphic adenoma of the parotid gland. *APMIS*, 123 (8):706-15.
  41. Meng F, Henson R, Wehbe-Janek H, et al (2007). MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. *Gastroenterology*, 133 (2):647-58.
  42. Zhu S, Si ML, Wu H, et al (2007). MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). *J Biol Chem*, 282 (19):14328-36.
  43. Dan T, Shastri AA, Palagani A, et al (2021). miR-21 Plays a Dual Role in Tumor Formation and Cytotoxic Response in Breast Tumors. *Cancers (Basel)*, 13 (4):888.
  44. Chen D, Cabay RJ, Jin Y, et al (2013). MicroRNA Deregulations in Head and Neck Squamous Cell Carcinomas. *J Oral Maxillofac Res*, 4 (1):e2.
  45. Cipriani NA, Lusardi JJ, McElherne J, et al (2019). Mucoepidermoid Carcinoma: A Comparison of Histologic Grading Systems and Relationship to MAML2 Rearrangement and Prognosis. *Am J Surg Pathol*, 43 (7):885-897.
  46. Kim BK, Yoo HI, Kim I, et al (2015). FZD6 expression is negatively regulated by miR-199a-5p in human colorectal cancer. *BMB Rep*, 48 (6):360-6.
  47. Zhou J, Liu R, Wang Y, et al (2014). miR-199a-5p regulates the expression of metastasis-associated genes in B16F10 melanoma cells. *Int J Clin Exp Pathol*, 7 (10):7182-90.
  48. Liu CJ, Kao SY, Tu HF, et al (2010). Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. *Oral Dis*, 16 (4):360-4.
  49. Chou CK, Yang KD, Chou FF, et al (2013). Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma. *J Clin Endocrinol Metab*, 98 (2):E196-205.
  50. Fuziwara CS, Kimura ET (2014). MicroRNA Deregulation in Anaplastic Thyroid Cancer Biology. *Int J Endocrinol*, 2014:743450.
  51. Brown AL, Al-Samadi A, Sperandio M, et al (2019). MiR-455-3p, miR-150 and miR-375

- are aberrantly expressed in salivary gland adenoid cystic carcinoma and polymorphous adenocarcinoma. *J Oral Pathol Med*, 48 (9):840-845.
52. Takamizawa J, Konishi H, Yanagisawa K, et al (2004). Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. *Cancer Res*, 64 (11):3753-6.
  53. Johnson SM, Grosshans H, Shingara J, et al (2005). RAS is regulated by the let-7 microRNA family. *Cell*, 120 (5):635-47.
  54. Bi Q, Tang S, Xia L, et al (2012). Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. *PLoS One*, 7 (6):e40169.
  55. Hsieh TH, Hsu CY, Tsai CF, et al (2015). miR-125a-5p is a prognostic biomarker that targets HDAC4 to suppress breast tumorigenesis. *Oncotarget*, 6 (1):494-509.
  56. Kim JK, Noh JH, Jung KH, et al (2013). Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. *Hepatology*, 57 (3):1055-67.
  57. Liang Y, Ye J, Jiao J, et al (2017). Down-regulation of miR-125a-5p is associated with salivary adenoid cystic carcinoma progression via targeting p38/JNK/ERK signal pathway. *Am J Transl Res*, 9 (3):1101-1113.
  58. Li L, Wang Y, Zhou X (2018). Tumor-suppressive effect of miR-148 a on salivary adenoid cystic carcinoma via down-regulation of MTA2. *Int J Clin Exp Med*, 11(11):11973-11980
  59. Stenman G, Sandros J, Mark J, Nordkvist A (1989). High p21RAS expression levels correlate with chromosome 8 rearrangements in benign human mixed salivary gland tumors. *Genes Chromosomes Cancer*, 1 (1):59-66.
  60. Calin GA, Sevignani C, Dumitru CD, et al (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. *Proc Natl Acad Sci U S A*, 101 (9):2999-3004.
  61. Oulas A, Boutla A, Gkirtzou K, et al (2009). Prediction of novel microRNA genes in cancer-associated genomic regions--a combined computational and experimental approach. *Nucleic Acids Res*, 37 (10):3276-87.